LL-37

Description

LL-37

Also known as: Cathelicidin, CAP18

LL-37 is a naturally occurring antimicrobial peptide belonging to the human cathelicidin family. It has drawn significant scientific attention for its roles in immune defence, wound repair, regulation of inflammation, skin regeneration, and antimicrobial activity. The peptide plays a role in the body’s response to bacterial, viral, and fungal challenges, as well as in tissue healing and immune communication. These characteristics have led to growing interest in LL-37 within regenerative medicine and biohacking circles, particularly among those exploring ways to enhance immunity, accelerate skin recovery, and optimize healing processes.

Key areas of research involving LL-37 include:
– Modulation of the immune system
– Support for wound and skin repair
– Studies on antimicrobial effects and biofilm interactions
– Inflammation control and tissue regeneration mechanisms

•Status: Currently under investigation in clinical trials focused on wound healing. Classified by the FDA as Category 2, meaning access is restricted—this restriction is likely to continue due to limited safety data and potential immunogenicity risks. Evidence based on human clinical trials.
•Common dosage: 100–200 mcg per day, administered once daily, either via subcutaneous injection or topical application.
•Studied for use in addressing antimicrobial resistance, treating infections, breaking down biofilms, and supporting wound healing.
Purchase available in store